HST Global Inc. EPS (Diluted)

EPS (Diluted) of HSTC for past 10 years: annual, quarterly and twelve month trailing (TTM) including EPS (Diluted) growth rates and interactive chart. Diluted earnings per share (EPS) tells investors how much of a firm's net income was allotted to each share of common stock. It is reported in a company's income statement and is especially informative for businesses with only common stock in their capital structures. Calculated as net income to common divided by the weighted average number of diluted shares outstanding (takes into account potential dilution from options or share issuance).

Highlights and Quick Summary

  • EPS (Diluted) for the quarter ending September 29, 2018 was 0.0 (a NaN% decrease compared to previous quarter)
  • Year-over-year quarterly EPS (Diluted) decreased by NaN%
  • Annual EPS (Diluted) for 2015 was -0.15 (a -0.0% decrease from previous year)
  • Annual EPS (Diluted) for 2014 was -0.15 (a -0.0% decrease from previous year)
  • Annual EPS (Diluted) for 2013 was -0.15 (a -0.0% decrease from previous year)
Visit stockrow.com/HSTC for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EPS (Diluted) of HST Global Inc.

Most recent EPS (Diluted)of HSTC including historical data for past 10 years.

Interactive Chart of EPS (Diluted) of HST Global Inc.

HST Global Inc. EPS (Diluted) for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2018 0.0 0.0 0.0
2017 0.0 0.0 0.0
2016 0.0 0.0 0.0
2015 0.0 0.0 0.0 0.0 -0.15
2014 0.0 0.0 0.0 0.0 -0.15
2013 0.0 0.0 0.0 0.0 -0.15
2012 0.0 0.0 0.0 0.0 -0.15
2011 -0.15 0.0 0.0 0.0 -0.15
2010 -0.15 -0.15 -0.15 -0.15 -0.45
2009 -0.15 -0.75

Business Profile of HST Global Inc.

Sector: Medical
Industry: Drugs
HST Global, Inc., an integrated health and wellness biotechnology company, develops and/or acquires a network of wellness centers for the homeopathic and alternative treatment of late stage cancer worldwide. It also focuses on the homeopathic and alternative product candidates that are undergoing or have already completed clinical testing for the treatment of late stage cancers and other life threatening diseases. The company also intends to acquire products for the treatment of individual health challenges. HST Global, Inc. is headquartered in Hampton, Virginia.